Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology
Open Access
- 18 March 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (6) , 3139
Abstract
This study sought to adapt the existing value framework (VF) to produce a reliable and valid Korean oncology VF. Two VFs developed by The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) were selected for examination in the present study. Forward and backward translations were conducted for six high-priced drugs indicated for non-small-cell lung cancer and multiple myeloma. Inter-rater reliability was measured based on the intraclass correlation coefficient (ICC) and variation was described using the coefficient of variation. The relative weights of factors critically considered by Korean oncologists were derived following the analytic hierarchy process (AHP), and focus group interviews (FGIs) were used to obtain qualitative data regarding the applications of these two VFs in the Korean setting. The ICCs of the Korean VFs were 0.895 (0.654–0.983) for ASCO and 0.726 (0–0.982) for ESMO translations, suggesting excellent reliability for ASCO and good reliability for ESMO. AHP demonstrated that clinical benefit has the highest priority, which is consistent with the ASCO VF. The FGIs suggested that the result for AHP is acceptable and that both ESMO and ASCO VFs should be used complementarily. Although further evaluation with a larger sample size is needed, the Korean versions of ESMO/ASCO VFs are valid and reliable tools and are acceptable to Korean stakeholders, yet they should be applied with caution.Keywords
Funding Information
- Health Insurance Review and Assessment Service (2019)
This publication has 28 references indexed in Scilit:
- An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical TrialsJAMA Oncology, 2016
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments ReceivedJournal of Clinical Oncology, 2016
- Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014JAMA Oncology, 2016
- Are high drug prices for hematologic malignancies justified? A critical analysisCancer, 2015
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)Annals of Oncology, 2015
- Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and CreativityJAMA Otolaryngology–Head & Neck Surgery, 2014
- From Translation to Version Management: A History and Review of Methods for the Cultural Adaptation of the EuroQol Five-Dimensional QuestionnaireValue in Health, 2014
- Market spiral pricing of cancer drugsCancer, 2013
- Sample size formulas for estimating intraclass correlation coefficients with precision and assuranceStatistics in Medicine, 2012
- The Role of the U.S. Food and Drug Administration Review Process: Clinical Trial Endpoints in OncologyThe Oncologist, 2010